MVA-SARS-CoV-2-ST Phase Ib vaccine trial

The MVA-SARS-CoV-2-ST study is a multi-center phase Ib trial to assess the safety, tolerability and immunogenicity of the candidate vaccine MVA-SARS-2-ST in adults to evaluate the safety, tolerability and reactogenicity of two intramuscular dose administrations of three dose levels of the candidate MVA-SARS-2-ST vaccine in healthy SARS-CoV-2 seronegative adults.

In addition, the study evaluates the safety, tolerability and reactogenicity of one intramuscular dose administration of three dose levels of the candidate MVA-SARS-2-ST vaccine in healthy adults previously vaccinated against COVID-19.

DZIF scientists at the LMU Munich , the Phillips-Universität in Marburg and the UKE Hamburg were able to start the development of a new vaccine against SARS-CoV-2. At the LMU Munich, Gerd Sutter's team created a stable MVA virus with a component of the corona virus. The company IDT-Biologika developed a cell line and a process that is the only way to produce a highly pure MVA vector vaccine on an industrial scale.

The trial is headed by Prof. Marylyn Addo and conducted at the Clinical Trial Center North . In Marburg, Prof. Stephan Becker's team will carry out immune monitoring - i.e. the characterisation of the antibody response to the vaccine.

clinicaltrial.gov
Corona vaccine development at the DZIF